OR WAIT null SECS
Provides clientele with an augmented drug development solution
WuXi STA—a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry—revealed that its first drug product continuous manufacturing (CM) line for oral solids is in operation at the drug product site located in Wuxi, China. This location has an integrated formulation development and manufacturing campus with comprehensive analytical platform for both oral and injectable formulations.
The CDMO notes that this new CM line offers customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market.
The company’s continuous manufacturing line features continuous direct compression equipment with unit operations including dispensing, blending, lubrication, tablet compression, and coating. The equipment design complies with the global current good manufacturing practice (cGMP) regulations. Process analytical technology is implemented within the CM line to monitor blending uniformity, allowing for real-time analysis, and control during production to ensure high product quality.
"I am glad that our first oral solid-dose drug product continuous manufacturing line has been launched in the Wuxi city site,” says Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA. “As a trusted partner and a global enabler, WuXi STA will continue to build first-class facilities with cutting-edge technologies to make more innovative medicines accessible to patients worldwide."
Read more about the new manufacturing line here.